BG
BMRN icon

BlackRock Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

BlackRock Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$90.4M Buy
1,091,545
+51,530
+5% +$4.43M 0.04% 456
2016
Q3 		$96.2M Buy
1,040,015
+16,645
+2% +$1.57M 0.05% 425
2016
Q2 		$79.6M Sell
1,023,370
-77,394
-7% -$6.58M 0.04% 460
2016
Q1 		$90.8M Sell
1,100,764
-385
-0% -$31.3K 0.05% 411
2015
Q4 		$115M Buy
1,101,149
+34,211
+3% +$3.57M 0.06% 348
2015
Q3 		$112M Sell
1,066,938
-8,498
-0.8% -$1.14M 0.07% 333
2015
Q2 		$147M Sell
1,075,436
-92,586
-8% -$11.5M 0.08% 282
2015
Q1 		$146M Sell
1,168,022
-54,128
-4% -$5.74M 0.08% 295
2014
Q4 		$110M Sell
1,222,150
-43,489
-3% -$3.62M 0.06% 365
2014
Q3 		$91.3M Buy
1,265,639
+105,888
+9% +$6.96M 0.05% 406
2014
Q2 		$72.1M Sell
1,159,751
-119,889
-9% -$7.24M 0.04% 466
2014
Q1 		$87.3M Buy
1,279,640
+544,559
+74% +$40.1M 0.05% 391
2013
Q4 		$51.7M Buy
735,081
+21,923
+3% +$1.49M 0.03% 534
2013
Q3 		$51.5M Buy
713,158
+228,100
+47% +$15.2M 0.03% 529
2013
Q2 		$27M Buy
+485,058
New +$30.2M 0.02% 644

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock Group's BMRN Position: Q4 2016 in Review

BlackRock Group increased its BioMarin Pharmaceuticals (BMRN) stake by 5% in Q4 2016, buying an estimated $4.43M and bringing the position to 1,091,545 shares worth $90.4M. The position accounts for 0.04% of the portfolio, ranked #456.

BlackRock Group first reported a position in BMRN in Q2 2013 and has held it in 15 quarters since. The position peaked at $147M in Q2 2015. 415 funds tracked by Wall St. Rank hold BMRN as of Q4 2016.

  • BlackRock Group held 1,091,545 shares of BioMarin Pharmaceuticals worth $90.4M as of Q4 2016.
  • BlackRock Group bought 51,530 BioMarin Pharmaceuticals shares in Q4 2016, an estimated $4.43M.
  • BioMarin Pharmaceuticals made up 0.04% of BlackRock Group's portfolio in Q4 2016, its #456 holding.
  • BlackRock Group first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Group's BioMarin Pharmaceuticals position peaked at $147M in Q2 2015.
  • 415 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.